171 related articles for article (PubMed ID: 17164991)
1. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study.
Tfelt-Hansen P; Bach FW; Daugaard D; Tsiropoulos I; Riddersholm B
J Headache Pain; 2006 Dec; 7(6):389-94. PubMed ID: 17164991
[TBL] [Abstract][Full Text] [Related]
2. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
[TBL] [Abstract][Full Text] [Related]
3. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
4. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study.
Carpay J; Schoenen J; Ahmad F; Kinrade F; Boswell D
Clin Ther; 2004 Feb; 26(2):214-23. PubMed ID: 15038944
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
8. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone.
Cleland PG; Barnes D; Elrington GM; Loizou LA; Rawes GD
Eur Neurol; 1997; 38(1):31-8. PubMed ID: 9252796
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
11. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
Landy S; Munjal S; Brand-Schieber E; Rapoport AM
J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets.
Savani N; Pfaffenrath V; Rice L; Boswell D; Black L; Jones M;
Clin Ther; 2001 Feb; 23(2):260-71. PubMed ID: 11293559
[TBL] [Abstract][Full Text] [Related]
14. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
15. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study.
Fujita M; Sato K; Nishioka H; Sakai F
Cephalalgia; 2014 Apr; 34(5):365-75. PubMed ID: 24163282
[TBL] [Abstract][Full Text] [Related]
16. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Winner P; Landy S; Richardson M; Ames M
Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449
[TBL] [Abstract][Full Text] [Related]
17. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group.
Savani N; Brautaset NJ; Reunanen M; Szirmai I; Ashford EA; Hassani H; Saiers J
Int J Clin Pract Suppl; 1999 Aug; 105():7-15. PubMed ID: 10692717
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
Seeburger JL; Taylor FR; Friedman D; Newman L; Ge Y; Zhang Y; Hustad CM; Lasorda J; Fan X; Hewitt D; Ho T; Connor KM
Cephalalgia; 2011 May; 31(7):786-96. PubMed ID: 21078681
[TBL] [Abstract][Full Text] [Related]
19. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Brandes JL; Kudrow D; Stark SR; O'Carroll CP; Adelman JU; O'Donnell FJ; Alexander WJ; Spruill SE; Barrett PS; Lener SE
JAMA; 2007 Apr; 297(13):1443-54. PubMed ID: 17405970
[TBL] [Abstract][Full Text] [Related]
20. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
